Zkusit zdarma
Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

NRIX
Cena:
$ 17.50
-0.03 (-0.17%)
Valuace
70
Růst
15
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

18:20 22-05-2026

Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Tr...

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

16:05 14-05-2026

In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune ce...

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics to Participate in Upcoming Investor Conferences

7:00 13-05-2026

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinic...

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

16:05 12-05-2026

BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinic...

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000

16:53 06-05-2026

Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sal...

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

7:00 22-04-2026

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs ...

Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

6:51 17-04-2026

Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transc...

Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?

Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?

10:56 10-04-2026

The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nu...

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

15:49 09-04-2026

Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg fo...

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates

8:12 08-04-2026

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.79 per share versus the Zacks C...

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

6:00 08-04-2026

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in re...

Nurix Therapeutics to Participate in Upcoming Investor Conference

Nurix Therapeutics to Participate in Upcoming Investor Conference

7:00 07-04-2026

BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clin...

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of “Moderate Buy” from Analysts

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of “Moderate Buy” from Analysts

2:38 06-04-2026

Shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) have earned a consensus rating o...

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

10:16 26-03-2026

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher ...

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

16:05 23-03-2026

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clin...

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

13:12 22-02-2026

Redmile Group increased its Nurix Therapeutics holding by 4,415,514 shares; the estimated trade valu...

Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight

Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight

1:02 16-02-2026

Executives from Nurix Therapeutics (NASDAQ: NRIX) used a recent discussion on the company's immunolo...

Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $60,772.60 in Stock

Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $60,772.60 in Stock

4:19 02-02-2026

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) CFO Houte Hans Van sold 3,661 shares of th...

Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $81,257.00 in Stock

Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $81,257.00 in Stock

4:19 02-02-2026

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) insider Gwenn Hansen sold 4,895 shares of ...

Head-To-Head Survey: Nurix Therapeutics (NASDAQ:NRIX) vs. Ultragenyx Pharmaceutical (NASDAQ:RARE)

Head-To-Head Survey: Nurix Therapeutics (NASDAQ:NRIX) vs. Ultragenyx Pharmaceutical (NASDAQ:RARE)

1:46 31-01-2026

Nurix Therapeutics (NASDAQ: NRIX - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Ge...

close

NURIX THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

28-01-2026
FIRST PATIENTS DOSED IN DAYBREAK™ REGISTRATIONAL PROGRAM FOR BEXOBRUTIDEG IN RELAPSED/REFRACTORY C...
Více zde

NURIX THERAPEUTICS OUTLINES 2026 GOALS AND OBJECTIVES FOR ADVANCING BEXOBRUTIDEG AND ITS PIPELINE OF NOVEL DEGRADER-BASED MEDICINES IN CANCER AND AUTOIMMUNE DISEASES

12-01-2026
EXECUTE A PIVOTAL PROGRAM FOR POTENTIAL BEST-IN-CLASS BTK DEGRADER, BEXOBRUTIDEG, INCLUDING PHASE 2 ...
Více zde

NURIX THERAPEUTICS TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

05-01-2026
BRISBANE, CALIF., JAN. 05, 2026 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINI...
Více zde

NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION

08-12-2025
OBJECTIVE RESPONSE RATE (ORR) OF 75.0% INCLUDING THREE VERY GOOD PARTIAL RESPONSES (VGPR) IN HEAVILY...
Více zde

NURIX THERAPEUTICS PRESENTS NEW DATA DEMONSTRATING DURABLE, DEEPENING RESPONSES IN PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL M

06-12-2025
OBJECTIVE RESPONSE RATE (ORR) OF 83% INCLUDING TWO COMPLETE RESPONSES IN CLL PATIENTS IN PHASE 1A ST...
Více zde

NURIX THERAPEUTICS ANNOUNCES WEBCAST TO REVIEW NEW AND UPDATED DATA FROM THE PHASE 1 CLINICAL TRIAL OF BTK DEGRADER BEXOBRUTIDEG (NX-5948) TO BE PRESENTED AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION

01-12-2025
SAN FRANCISCO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

25-11-2025
SAN FRANCISCO, NOV. 25, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS APPOINTS ACCOMPLISHED BIOPHARMACEUTICAL LEADER ROGER DANSEY, M.D., TO ITS BOARD OF DIRECTORS

10-11-2025
DR. DANSEY, FORMERLY OF PFIZER AND SEAGEN, STRENGTHENS THE BOARD'S RESEARCH, DRUG DEVELOPMENT AND C...
Více zde

NURIX THERAPEUTICS PRESENTS NEW TRANSLATIONAL DATA FROM FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL CBL-B INHIBITOR NX-1607 DEMONSTRATING IMMUNE ACTIVATION AND TUMOR MICROENVIRONMENT REMODELING

07-11-2025
SAN FRANCISCO, NOV. 07, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS ANNOUNCES PRESENTATIONS AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

03-11-2025
SAN FRANCISCO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

30-10-2025
SAN FRANCISCO, OCT. 30, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS ANNOUNCES CLOSING OF $250.0 MILLION REGISTERED OFFERING OF COMMON STOCK

27-10-2025
SAN FRANCISCO, OCT. 27, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS ANNOUNCES $250.0 MILLION REGISTERED OFFERING OF COMMON STOCK

22-10-2025
SAN FRANCISCO, OCT. 22, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX INITIATES DAYBREAK™ PIVOTAL STUDY OF BEXOBRUTIDEG IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

22-10-2025
600 MG ONCE DAILY BEXOBRUTIDEG ORAL DOSE CLEARED BY GLOBAL REGULATORS FOR PIVOTAL MONOTHERAPY TRIALS...
Více zde

NURIX THERAPEUTICS REPORTS NEW CLINICAL DATA FROM FIRST-IN-CLASS ORAL CBL-B INHIBITOR, NX-1607, DEMONSTRATING SINGLE-AGENT ACTIVITY ACROSS MULTIPLE TUMOR TYPES AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS

18-10-2025
NX-1607 DEMONSTRATED ON-TARGET PERIPHERAL IMMUNE ACTIVATION CHARACTERISTIC OF AN ACTIVE IMMUNE-ONCOL...
Více zde

NURIX THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

09-10-2025
ANNOUNCED CLINICAL DEVELOPMENT PLANS FOR BEXOBRUTIDEG, INCLUDING THE INITIATION OF PIVOTAL TRIALS IN...
Více zde

NURIX THERAPEUTICS PRESENTS PRECLINICAL DATA FROM NOVEL IRAK4 DEGRADER, GS-6791, DEMONSTRATING POTENT INHIBITION OF IL-1 AND IL-36 IN VITRO AND EFFICACY IN A MODEL OF DERMATITIS

17-09-2025
PRESENTATION OF PRECLINICAL DATA FROM NOVEL IRAK4 PROTEIN DEGRADER, GS-6791, DISCOVERED IN NURIX'S O...
Více zde

NURIX THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

28-08-2025
SAN FRANCISCO, AUG. 28, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

09-07-2025
PRESENTED UPDATED DATA FOR BEXOBRUTIDEG (NX-5948) AT EHA2025 AND ICML-18, DEMONSTRATING A FAVORABLE ...
Více zde

EUROPEAN MEDICINES AGENCY GRANTS BEXOBRUTIDEG (NX-5948) ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF LYMPHOPLASMACYTIC LYMPHOMA, ALSO KNOWN AS WALDENSTRÖM MACROGLOBULINEMIA

07-07-2025
SAN FRANCISCO, JULY 07, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

13-06-2025
SAN FRANCISCO, JUNE 13, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

NURIX THERAPEUTICS PRESENTS UPDATED POSITIVE DATA DEMONSTRATING DURABLE, DEEPENING RESPONSES IN ONGOING CLINICAL TRIAL OF BEXOBRUTIDEG (NX-5948) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND WALDENSTRÖM MACROGLOBU

12-06-2025
COMPLETE RESPONSE ACHIEVED IN CLL; OVERALL OBJECTIVE RESPONSE RATE OF 80.9% IN CLL PATIENTS AND 84.2...
Více zde

NURIX THERAPEUTICS TO HOST A WEBCAST CONFERENCE CALL TO DISCUSS DATA FROM THE ONGOING PHASE 1 CLINICAL TRIAL OF BEXOBRUTIDEG (NX-5948) BEING PRESENTED AT THE 30TH EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS (EHA2025)

06-06-2025
SAN FRANCISCO, JUNE 06, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL...
Více zde

SANOFI EXERCISES LICENSE EXTENSION OPTION TO NURIX'S STAT6 PROGRAM

02-06-2025
STAT6 IS A KEY TRANSCRIPTION FACTOR WITHIN THE IL4/IL13 SIGNALING PATHWAYS WHICH ACT AS DRIVERS OF I...
Více zde

NURIX THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

28-05-2025
SAN FRANCISCO, MAY 28, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL-...
Více zde

NURIX THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

16-05-2025
SAN FRANCISCO, MAY 16, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL-...
Více zde

NURIX THERAPEUTICS TO PARTICIPATE IN THE RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

15-05-2025
SAN FRANCISCO, MAY 15, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL-...
Více zde

NURIX THERAPEUTICS ANNOUNCES PRESENTATIONS OF CLINICAL DATA AT THE 30TH EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS AND THE 18TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

14-05-2025
SAN FRANCISCO, MAY 14, 2025 (GLOBE NEWSWIRE) -- NURIX THERAPEUTICS, INC. (NASDAQ: NRIX), A CLINICAL-...
Více zde

NURIX THERAPEUTICS PRESENTS DATA AT THE AACR 2025 ANNUAL MEETING HIGHLIGHTING THE TRANSFORMATIVE POTENTIAL OF ITS PROPRIETARY DEL-AI PLATFORM LEVERAGING MACHINE LEARNING TO SPEED THE DISCOVERY OF NOVEL DRUGS

28-04-2025
NURIX'S DEL-AI PLATFORM USES A FIRST-IN-CLASS DEL FOUNDATION MODEL TRAINED ON THE  COMPANY'S PROPRI...
Více zde

NURIX THERAPEUTICS PRESENTS POSITIVE PRECLINICAL DATA AT THE AACR 2025 ANNUAL MEETING FROM MULTIPLE ORALLY AVAILABLE, BRAIN PENETRANT DEGRADERS AGAINST THREE HIGH VALUE ONCOLOGY TARGETS

25-04-2025
NURIX'S LEAD BTK DEGRADER, BEXOBRUTIDEG, DEMONSTRATES EXCEPTIONAL EFFICIENCY, WITH A SINGLE MOLECULE...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-28 00:00:008-KStáhnout
2026-01-28 00:00:0010-KStáhnout
2026-01-12 00:00:008-KStáhnout
2025-12-09 00:00:008-KStáhnout
2025-11-10 00:00:008-KStáhnout
2025-10-22 01:00:008-KStáhnout
2025-10-22 00:00:008-KStáhnout
2025-10-09 01:00:008-KStáhnout
2025-10-09 01:00:0010-QStáhnout
2025-10-09 00:00:008-KStáhnout
2025-10-09 00:00:0010-QStáhnout
2025-09-03 01:00:008-KStáhnout
2025-09-03 00:00:008-KStáhnout
2025-08-22 01:00:008-KStáhnout
2025-08-22 00:00:008-KStáhnout
2025-07-09 01:00:008-KStáhnout
2025-07-09 01:00:0010-QStáhnout
2025-07-09 00:00:008-KStáhnout
2025-07-09 00:00:0010-QStáhnout
2025-06-12 01:00:008-KStáhnout
2025-06-12 00:00:008-KStáhnout
2025-05-19 01:00:008-KStáhnout
2025-05-19 00:00:008-KStáhnout
2025-04-08 01:00:008-KStáhnout
2025-04-08 01:00:0010-QStáhnout
2025-04-08 00:00:008-KStáhnout
2025-04-08 00:00:0010-QStáhnout
2025-03-13 00:00:008-KStáhnout
2025-03-12 23:00:008-KStáhnout
2025-01-28 00:00:008-KStáhnout
2025-01-28 00:00:0010-KStáhnout
2025-01-27 23:00:008-KStáhnout
2025-01-27 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-12-10 00:00:008-KStáhnout
2024-12-09 23:00:008-KStáhnout
2024-10-31 00:00:008-KStáhnout
2024-10-30 23:00:008-KStáhnout
2024-10-16 01:00:008-KStáhnout
2024-10-16 00:00:008-KStáhnout
2024-10-11 01:00:008-KStáhnout
2024-10-11 01:00:0010-QStáhnout
2024-10-11 00:00:008-KStáhnout
2024-10-11 00:00:0010-QStáhnout
2024-09-05 01:00:008-KStáhnout
2024-09-05 00:00:008-KStáhnout
2024-07-11 01:00:008-KStáhnout
2024-07-11 01:00:0010-QStáhnout
2024-07-11 00:00:008-KStáhnout
2024-07-11 00:00:0010-QStáhnout
2024-06-17 01:00:008-KStáhnout
2024-06-17 00:00:008-KStáhnout
2024-05-21 01:00:008-KStáhnout
2024-05-21 00:00:008-KStáhnout
2024-04-12 01:00:008-KStáhnout
2024-04-12 00:00:008-KStáhnout
2024-04-10 01:00:008-KStáhnout
2024-04-10 01:00:0010-QStáhnout
2024-04-10 00:00:008-KStáhnout
2024-04-10 00:00:0010-QStáhnout
2024-04-09 01:00:008-KStáhnout
2024-04-09 00:00:008-KStáhnout
2024-03-11 00:00:008-KStáhnout
2024-03-10 23:00:008-KStáhnout
2024-02-15 00:00:008-KStáhnout
2024-02-15 00:00:0010-KStáhnout
2024-02-14 23:00:008-KStáhnout
2024-02-14 23:00:0010-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-12-11 00:00:008-KStáhnout
2023-12-10 23:00:008-KStáhnout
2023-11-13 00:00:008-KStáhnout
2023-11-12 23:00:008-KStáhnout
2023-11-01 00:00:008-KStáhnout
2023-10-31 23:00:008-KStáhnout
2023-10-12 01:00:008-KStáhnout
2023-10-12 01:00:0010-QStáhnout
2023-10-12 00:00:008-KStáhnout
2023-10-12 00:00:0010-QStáhnout
2023-09-07 01:00:008-KStáhnout
2023-09-07 00:00:008-KStáhnout
2023-07-13 01:00:008-KStáhnout
2023-07-13 01:00:0010-QStáhnout
2023-07-13 00:00:008-KStáhnout
2023-07-13 00:00:0010-QStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 00:00:008-KStáhnout
2023-04-13 01:00:008-KStáhnout
2023-04-13 01:00:0010-QStáhnout
2023-04-13 00:00:008-KStáhnout
2023-04-13 00:00:0010-QStáhnout
2023-04-10 01:00:008-KStáhnout
2023-04-10 00:00:008-KStáhnout
2023-03-13 00:00:008-KStáhnout
2023-03-12 23:00:008-KStáhnout
2023-02-09 00:00:008-KStáhnout
2023-02-09 00:00:0010-KStáhnout
2023-02-08 23:00:008-KStáhnout
2023-02-08 23:00:0010-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-16 00:00:008-KStáhnout
2022-12-15 23:00:008-KStáhnout
2022-12-13 00:00:008-KStáhnout
2022-12-12 23:00:008-KStáhnout
2022-10-26 01:00:008-KStáhnout
2022-10-26 00:00:008-KStáhnout
2022-10-06 01:00:008-KStáhnout
2022-10-06 01:00:0010-QStáhnout
2022-10-06 00:00:008-KStáhnout
2022-10-06 00:00:0010-QStáhnout
2022-09-14 01:00:008-KStáhnout
2022-09-14 00:00:008-KStáhnout
2022-07-08 01:00:008-KStáhnout
2022-07-08 00:00:008-KStáhnout
2022-07-07 01:00:008-KStáhnout
2022-07-07 01:00:0010-QStáhnout
2022-07-07 00:00:008-KStáhnout
2022-07-07 00:00:0010-QStáhnout
2022-05-26 01:00:008-KStáhnout
2022-05-26 00:00:008-KStáhnout
2022-05-16 01:00:008-KStáhnout
2022-05-16 00:00:008-KStáhnout
2022-05-06 01:00:008-KStáhnout
2022-05-06 00:00:008-KStáhnout
2022-04-08 01:00:0010-QStáhnout
2022-04-08 00:00:0010-QStáhnout
2022-04-07 01:00:008-KStáhnout
2022-04-07 00:00:008-KStáhnout
2022-03-07 00:00:008-KStáhnout
2022-03-06 23:00:008-KStáhnout
2022-03-02 00:00:008-KStáhnout
2022-03-01 23:00:008-KStáhnout
2022-01-28 00:00:0010-KStáhnout
2022-01-27 23:00:0010-KStáhnout
2022-01-27 00:00:008-KStáhnout
2022-01-26 23:00:008-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-10-27 01:00:008-KStáhnout
2021-10-27 00:00:008-KStáhnout
2021-10-14 01:00:008-KStáhnout
2021-10-14 01:00:0010-QStáhnout
2021-10-14 00:00:008-KStáhnout
2021-10-14 00:00:0010-QStáhnout
2021-09-30 01:00:008-KStáhnout
2021-09-30 00:00:008-KStáhnout
2021-07-13 01:00:008-KStáhnout
2021-07-13 01:00:0010-QStáhnout
2021-07-13 00:00:008-KStáhnout
2021-07-13 00:00:0010-QStáhnout
2021-07-09 01:00:008-KStáhnout
2021-07-09 00:00:008-KStáhnout
2021-06-21 01:00:008-KStáhnout
2021-06-21 00:00:008-KStáhnout
2021-06-02 01:00:008-KStáhnout
2021-06-02 00:00:008-KStáhnout
2021-06-01 01:00:008-KStáhnout
2021-06-01 00:00:008-KStáhnout
2021-05-10 01:00:008-KStáhnout
2021-05-10 00:00:008-KStáhnout
2021-04-13 01:00:008-KStáhnout
2021-04-13 01:00:0010-QStáhnout
2021-04-13 00:00:008-KStáhnout
2021-04-13 00:00:0010-QStáhnout
2021-02-16 00:00:008-KStáhnout
2021-02-16 00:00:0010-KStáhnout
2021-02-15 23:00:008-KStáhnout
2021-02-15 23:00:0010-KStáhnout
2020-12-07 00:00:008-KStáhnout
2020-12-06 23:00:008-KStáhnout
2020-10-26 00:00:008-KStáhnout
2020-10-25 23:00:008-KStáhnout
2020-10-14 01:00:008-KStáhnout
2020-10-14 01:00:0010-QStáhnout
2020-10-14 00:00:008-KStáhnout
2020-10-14 00:00:0010-QStáhnout
preloader